ClinicaliQ Trial Snapshot
- Developing Trustworthy Artificial Intelligence (AI)-Driven Tools to Predict Vascular Disease Risk and Progression — Recruiting • Cardiology / Cardiovascular • NCT06206369.
- What is being tested: Development of AI algorithms designed to predict cardiovascular events and disease progression in abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD) using retrospective clinical data analysis.
- Patient eligibility overview: The study includes patients with existing or suspected vascular disease (AAA and PAD), with retrospective data collection from healthcare records to train and validate the AI prediction models.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The VASCULAID-RETRO study, within the broader VASCULAID project, aims to create artificial intelligence (AI) algorithms that can predict cardiovascular events and the progression of abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD). The study plans to gather and analyze data from at least 5000 AAA and 6000 PAD patients, combining existing cohorts and retrospectively collected data. During this project, AI tools will be developed to perform automatic anatomical segmentation and analyses on multimodal imaging. AI prediction algorithms will be developed based on multisource data (imaging, medical history, -omics).
Eligibility Snapshot
- AAA: * Males and females * 40-90 years old, * Infrarenal, juxtarenal, suprarenal, iliac aneurysms (defined as 1.5x its normal diameter), and mycotic aneurysms. * Starting AAA diameter >3cm, * Patients that both have had or did not have interventions or ruptures.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.